

# Jan Booij

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/659656/publications.pdf>

Version: 2024-02-01

72  
papers

2,154  
citations

257101

24  
h-index

243296

44  
g-index

75  
all docs

75  
docs citations

75  
times ranked

3088  
citing authors

#	ARTICLE	IF	CITATIONS
1	The clinical benefit of imaging striatal dopamine transporters with [123I]FP-CIT SPET in differentiating patients with presynaptic parkinsonism from those with other forms of parkinsonism. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 266-272.	2.2	230
2	Dermal phospho-alpha-synuclein deposits confirm REM sleep behaviour disorder as prodromal Parkinson's disease. <i>Acta Neuropathologica</i> , 2017, 133, 535-545.	3.9	195
3	Dopamine transporter imaging with [123I]FP-CIT SPECT: potential effects of drugs. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 424-438.	3.3	145
4	[123I]FP-CIT binds to the dopamine transporter as assessed by biodistribution studies in rats and SPECT studies in MPTP-lesioned monkeys. <i>Synapse</i> , 1997, 27, 183-190.	0.6	94
5	The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review. <i>EJNMMI Research</i> , 2015, 5, 12.	1.1	91
6	Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. <i>Journal of Nuclear Medicine</i> , 2007, 48, 359-66.	2.8	88
7	Imaging of dopamine transporters with [123I]FP-CIT SPECT does not suggest a significant effect of age on the symptomatic threshold of disease in Parkinson's disease. <i>Synapse</i> , 2001, 39, 101-108.	0.6	65
8	Striatal dopaminergic modulation of reinforcement learning predicts reward-oriented behavior in daily life. <i>Biological Psychology</i> , 2017, 127, 1-9.	1.1	60
9	Human biodistribution and dosimetry of [ 123 I]FP-CIT: a potent radioligand for imaging of dopamine transporters. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1997, 25, 24-30.	3.3	56
10	Increased Release of Dopamine in the Striata of Young Adults With Hearing Impairment and Its Relevance for the Social Defeat Hypothesis of Schizophrenia. <i>JAMA Psychiatry</i> , 2014, 71, 1364.	6.0	52
11	Being impulsive and obese increases susceptibility to speeded detection of high-calorie foods.. <i>Health Psychology</i> , 2015, 34, 677-685.	1.3	52
12	[123I]FP-CIT ENC-DAT normal database: the impact of the reconstruction and quantification methods. <i>EJNMMI Physics</i> , 2017, 4, 8.	1.3	46
13	Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002, 29, 1221-1224.	3.3	44
14	SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2007, 13, S425-S428.	1.1	44
15	Diagnostic Performance of the Visual Reading of <sup>123</sup> I-Ioflupane SPECT Images With or Without Quantification in Patients With Movement Disorders or Dementia. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1821-1826.	2.8	44
16	The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 353-357.	3.3	44
17	The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies. <i>Psychopharmacology</i> , 2016, 233, 3473-3501.	1.5	35
18	Reduction in camera-specific variability in [123I]FP-CIT SPECT outcome measures by image reconstruction optimized for multisite settings: impact on age-dependence of the specific binding ratio in the ENC-DAT database of healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1323-1336.	3.3	35

#	ARTICLE	IF	CITATIONS
19	Association of central serotonin transporter availability and body mass index in healthy Europeans. <i>European Neuropsychopharmacology</i> , 2014, 24, 1240-1247.	0.3	34
20	Personality as a risk factor for illicit opioid use and a protective factor for illicit opioid dependence. <i>Drug and Alcohol Dependence</i> , 2014, 145, 101-105.	1.6	29
21	Implementation of the European multicentre database of healthy controls for [ <sup>123</sup> I]FP-CIT SPECT increases diagnostic accuracy in patients with clinically uncertain parkinsonian syndromes. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1315-1322.	3.3	29
22	Reliability and Reproducibility of Neuromelanin-Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 712-721.	1.9	29
23	Late onset depression: dopaminergic deficit and clinical features of prodromal Parkinson's disease: a cross-sectional study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 158-164.	0.9	29
24	Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. <i>Journal of Psychopharmacology</i> , 2014, 28, 553-560.	2.0	27
25	Relationship between muscarinic M1 receptor binding and cognition in medication-free subjects with psychosis. <i>NeuroImage: Clinical</i> , 2018, 18, 713-719.	1.4	26
26	Rigidity decreases resting tremor intensity in Parkinson's disease: A [ <sup>123</sup> I]-CIT SPECT study in early, nonmedicated patients. <i>Movement Disorders</i> , 2001, 16, 1033-1040.	2.2	25
27	Dopaminergic System Dysfunction in Recreational Dexamphetamine Users. <i>Neuropsychopharmacology</i> , 2015, 40, 1172-1180.	2.8	25
28	Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. <i>PLoS ONE</i> , 2016, 11, e0159928.	1.1	23
29	Timing of caloric intake during weight loss differentially affects striatal dopamine transporter and thalamic serotonin transporter binding. <i>FASEB Journal</i> , 2017, 31, 4345-4554.	0.2	23
30	Imaging of striatal dopamine transporters in rat brain with single pinhole SPECT and co-aligned MRI is highly reproducible. <i>Nuclear Medicine and Biology</i> , 2003, 30, 643-649.	0.3	22
31	<sup>123</sup> I-Iododexetimide Preferentially Binds to the Muscarinic Receptor Subtype M <sub>1</sub> In Vivo. <i>Journal of Nuclear Medicine</i> , 2015, 56, 317-322.	2.8	22
32	Novel molecular imaging ligands targeting matrix metalloproteinases 2 and 9 for imaging of unstable atherosclerotic plaques. <i>PLoS ONE</i> , 2017, 12, e0187767.	1.1	22
33	Hunting for the high-affinity state of G-protein-coupled receptors with agonist tracers: Theoretical and practical considerations for positron emission tomography imaging. <i>Medicinal Research Reviews</i> , 2019, 39, 1014-1052.	5.0	22
34	3-D Rat Brain Phantom for High-Resolution Molecular Imaging. <i>Proceedings of the IEEE</i> , 2009, 97, 1997-2005.	16.4	19
35	Quantitative classification and radiomics of [ <sup>18</sup> F]FDG-PET/CT in indeterminate thyroid nodules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 2174-2188.	3.3	19
36	Relationships between Serotonin Transporter Binding in the Raphe Nuclei, Basal Ganglia, and Hippocampus with Clinical Symptoms in Cervical Dystonia: A [ <sup>11</sup> C]DASB Positron Emission Tomography Study. <i>Frontiers in Neurology</i> , 2018, 9, 88.	1.1	18

#	ARTICLE	IF	CITATIONS
37	Brain kinetics of the new selective serotonin transporter tracer [ <sup>123</sup> I]ADAM in healthy young adults. <i>Nuclear Medicine and Biology</i> , 2006, 33, 185-191.	0.3	17
38	Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder. <i>Psychiatry Research - Neuroimaging</i> , 2014, 221, 155-161.	0.9	17
39	Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using <sup>123</sup> I-Hoflupane Injection (DaTscan) Imaging. <i>Journal of Nuclear Medicine</i> , 2014, 55, 1288-1296.	2.8	17
40	Iodine-123 labelled nor- <sup>125</sup> I-CIT binds to the serotonin transporter in vivo as assessed by biodistribution studies in rats. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998, 25, 1666-1669.	3.3	16
41	The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [ <sup>123</sup> I]FP-CIT SPECT imaging. <i>EJNMMI Research</i> , 2017, 7, 10.	1.1	16
42	Serotonin transporter occupancy by the SSRI citalopram predicts default-mode network connectivity. <i>European Neuropsychopharmacology</i> , 2018, 28, 1173-1179.	0.3	15
43	Intact striatal dopaminergic modulation of reward learning and daily-life reward-oriented behavior in first-degree relatives of individuals with psychotic disorder. <i>Psychological Medicine</i> , 2018, 48, 1909-1914.	2.7	14
44	Affective and psychotic reactivity to daily-life stress in adults with 22q11DS: a study using the experience sampling method. <i>Journal of Neurodevelopmental Disorders</i> , 2020, 12, 30.	1.5	14
45	In vitro and in vivo characterization of newly developed iodinated 1-{2-[Bis(4-fluorophenyl)methoxy]ethyl}piperazine derivatives in rats: Limited value as dopamine transporter SPECT ligands. , 1996, 23, 201-207.		12
46	Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway. <i>Journal of the Neurological Sciences</i> , 2011, 310, 40-43.	0.3	11
47	Reactivity to social stress in ethnic minority men. <i>Psychiatry Research</i> , 2016, 246, 629-636.	1.7	11
48	Risk factors for nonvisualization of the sentinel lymph node on lymphoscintigraphy in breast cancer patients. <i>EJNMMI Research</i> , 2021, 11, 54.	1.1	11
49	Acute Administration of Haloperidol Does Not Influence <sup>123</sup> I-FP-CIT Binding to the Dopamine Transporter. <i>Journal of Nuclear Medicine</i> , 2014, 55, 647-649.	2.8	10
50	Dopamine transporter occupancy by methylphenidate and impulsivity in adult ADHD. <i>British Journal of Psychiatry</i> , 2014, 204, 486-487.	1.7	10
51	Reduced striatal dopamine D <sub>2/3</sub> receptor availability in Body Dysmorphic Disorder. <i>European Neuropsychopharmacology</i> , 2016, 26, 350-356.	0.3	10
52	Increase in central striatal dopamine transporters in patients with Shwachman's "Diamond syndrome: Additional evidence of a brain phenotype. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 102-107.	0.7	9
53	Imaging as Tool to Investigate Psychoses and Antipsychotics. <i>Handbook of Experimental Pharmacology</i> , 2012, , 299-337.	0.9	8
54	Daily-life stress differentially impacts ventral striatal dopaminergic modulation of reward processing in first-degree relatives of individuals with psychosis. <i>European Neuropsychopharmacology</i> , 2018, 28, 1314-1324.	0.3	7

#	ARTICLE	IF	CITATIONS
55	The muscarinic M1 receptor modulates associative learning and memory in psychotic disorders. <i>NeuroImage: Clinical</i> , 2020, 27, 102278.	1.4	7
56	Repeated dexamphetamine treatment alters the dopaminergic system and increases the pHMRI response to methylphenidate. <i>PLoS ONE</i> , 2017, 12, e0172776.	1.1	7
57	Synthesis and Evaluation in Rats of the Dopamine D2/3 Receptor Agonist 18F-AMC20 as a Potential Radioligand for PET. <i>Journal of Nuclear Medicine</i> , 2015, 56, 133-139.	2.8	6
58	Reliability of visual assessment by non-expert nuclear medicine physicians and appropriateness of indications of [ <sup>123</sup> I]FP-CIT SPECT imaging by neurologists in patients with early drug-naïve Parkinson's disease. <i>EJNMMI Research</i> , 2019, 9, 63.	1.1	6
59	Human in vivo neuroimaging to detect reprogramming of the cerebral immune response following repeated systemic inflammation. <i>Brain, Behavior, and Immunity</i> , 2021, 95, 321-329.	2.0	6
60	<sup>68</sup> Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 4.	0.6	5
61	Agonist signalling properties of radiotracers used for imaging of dopamine D2/3 receptors. <i>EJNMMI Research</i> , 2014, 4, 53.	1.1	4
62	Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). <i>Journal of Parkinson's Disease</i> , 2020, 10, 1561-1569.	1.5	4
63	Paraneoplastic Cerebellar Syndrome Presented as Cerebellar Hypermetabolism in a Patient With Occult Breast Carcinoma. <i>Clinical Nuclear Medicine</i> , 2022, 47, 130-132.	0.7	4
64	Dopaminergic alterations in populations at increased risk for psychosis: A systematic review of imaging findings. <i>Progress in Neurobiology</i> , 2022, 213, 102265.	2.8	4
65	Subchronic administration of short-acting naltrexone has no effect on striatal dopamine transporter availability, food intake or body weight gain in rats. <i>Journal of Psychopharmacology</i> , 2015, 29, 344-348.	2.0	3
66	QT prolongation by dexamphetamine: Does experience matter?. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 912-916.	0.8	2
67	The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a <sup>68</sup> Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lanreotide on tumour size. <i>BMJ Open</i> , 2020, 10, e038250.	0.8	2
68	Unexpected Detection of Nodular Melanoma of the Skin on the Scalp by I-123 IBZM Brain SPECT. <i>Clinical Nuclear Medicine</i> , 2011, 36, 148-149.	0.7	1
69	Cardiac sympathetic activity in 22q11.2 deletion syndrome. <i>International Journal of Cardiology</i> , 2016, 212, 346-351.	0.8	1
70	Ex Vivo Characterization of a Novel Iodine-123-Labelled Aminomethylchroman as a Potential Agonist Ligand for SPECT Imaging of Dopamine D2/3 Receptors. <i>International Journal of Molecular Imaging</i> , 2014, 2014, 1-10.	1.3	0
71	Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531987234.	1.2	0
72	Detection of an undescended parathyroid adenoma with 18F-fluorocholine PET/CT. <i>European Journal of Hybrid Imaging</i> , 2022, 6, 10.	0.6	0